Ranitidine (Zantac®) syrup versus ranitidine effervescent tablets (Zantac® EFFERdose®) in children: A single-center taste preference study

被引：22

作者：

Ameen V.Z. ^{[1
,4
]}

Pobiner B.F. ^{[2
]}

Giguere G.C. ^{[3
]}

Carter E.G. ^{[2
]}

机构：

[1] Clinical Pharmacology and Discovery Medicine, Research and Development, GlaxoSmithKline, Research Triangle Park, NC

[2] Gastroenterology Medicine Development Center, GlaxoSmithKline, Research Triangle Park, NC

[3] Department of Biostatistics and Programming, GlaxoSmithKline, Research Triangle Park, NC

[4] GlaxoSmithKline, Research Triangle Park, NC 27709

来源：

Pediatric Drugs | 2006年 / 8卷 / 4期

关键词：

Ranitidine; Lansoprazole; Famotidine; Erosive Esophagitis; Taste Preference;

D O I：

10.2165/00148581-200608040-00005

中图分类号：

学科分类号：

摘要：

Background: The histamine H2 receptor antagonist ranitidine is US FDA-approved for the treatment of gastroesophageal reflux disease and healing of erosive esophagitis in children ≥1 month of age. A low-dose strength of ranitidine is now available in a citrus-flavored 25mg effervescent tablet (dissolved in 5mL of water); this formulation was developed to facilitate use in infants and smaller children. Ranitidine syrup is available in a peppermint-flavored 15 mg/mL formulation. Objective: To compare taste preferences for ranitidine (Zantac®) syrup and ranitidine effervescent tablets dissolved in water (Zantac® EFFERdose®) in healthy children aged 4-8 years and their adult caregivers. Study Design and Methods: A randomized, single-blind, crossover, taste test trial was conducted in 102 children and 102 parents/legal guardians. All subjects received a single 45mg dose of each formulation. After tasting both preparations children were asked: "Now that you have tasted both medicines, which one of these medicines do you think tastes better?" Adults were asked four questions to assess whether they would administer the medication to the children. Results: Seventy-one percent (72/102) of the children preferred the taste of the ranitidine effervescent tablets compared with 29% (30/102) who preferred the syrup (p < 0.001). The majority of adults (71%) responded that they would prefer to administer the effervescent formulation based on taste. Adverse events consistent with product labeling were mild and were reported in four children and three adults: headache (n = 3), drowsiness (n = 1), abdominal pain/cramps (n = 2), and bloating/gas (n = 1). Conclusion: The taste of the ranitidine effervescent formulation dissolved in water is preferred over the ranitidine syrup. Better taste acceptance may facilitate ease of administration and compliance in pediatric patients. © 2006 Adis Data Information BV. All rights reserved.

引用

页码：265 / 270

页数：5

共 19 条

[1]

Rudolph C.D., Supraesophageal complications of gastroesophageal reflux in children: Challenges in diagnosis and treatment, Am J Med, 115, SUPPL. 3A, (2003)

[2]

Rudolph C.D., Mazur L.J., Liptak G.S., Et al., Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: Recommendations of the North American Society for Pediatric Gastroenterology and Nutrition, J Pediatr Gastroenterol Nutr, 32, 2 SUPPL., (2001)

[3]

Shepherd R.W., Wren J., Evans S., Et al., Gastroesophageal reflux in children: Clinical profile, course and outcome with active therapy in 126 cases, Clin Pediatr, 26, pp. 55-60, (1987)

[4]

Nelson S.P., Chen E.H., Syniar G.M., Et al., Prevalence of symptoms of gastroesophageal reflux during infancy: A pediatric practice-based survey, Arch Pediatr Adolesc Med, 151, pp. 569-572, (1997)

[5]

Nelson S.P., Chen E.H., Syniar G.M., Et al., Prevalence of symptoms of gastroesophageal reflux during childhood: A pediatric practice-based survey, Arch Pediatr Adolesc Med, 154, pp. 150-154, (2000)

[6]

El-Serag H.B., Gilger M., Carter J., Et al., Childhood GERD is a risk factor for GERD in adolescents and young adults, Am J Gastroenterol, 99, pp. 806-812, (2004)

[7]

Mallet E., Mouterde O., Dubois F., Et al., Use of ranitidine in young infants with gastro-oesophageal reflux, Eur J Clin Pharmacol, 36, pp. 641-642, (1989)

[8]

Goudsouzian N.G., Young E.T., The efficacy of ranitidine in children, Acta Anaesthesiol Scand, 31, pp. 387-390, (1987)

[9]

Blumer J.L., Rothstein F.C., Kaplan B.S., Et al., Pharmacokinetic determination of ranitidine pharmacodynamics in pediatric ulcer disease, J Pediatr, 107, pp. 301-306, (1985)

[10]

Winnick S., Lucas D.O., Hartman A.L., Et al., How do you improve compliance?, Pediatrics, 115, (2005)

← 1 2 →